|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2006-7-28
|
|
pubmed:abstractText |
Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ AML. We conducted a retrospective multicenter study of 12 children treated with GO on a compassionate basis (median age 5.5 y). Three patients (2 MDS/AML, 1 JMML) were refractory to first-line treatment, 8 patients with de novo AML were in refractory first relapse, and one patient with de novo AML was in 2nd relapse after stem cell transplantation (SCT). CD33 expression exceeded 20% in all cases.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-10339474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-10358698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-10519984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11352963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11378544,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11410481,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11432892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11466696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11792178,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11895761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-11970768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-12065553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-12105773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-12543868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-12738663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-12933575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-1346800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-15249716,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-15886328,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-1671875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-2469766,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-7579404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-8324745,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-8501490,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-8544799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-8652810,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-9576193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16805911-9722289
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aminoglycosides,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CD33 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Immunotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/gemtuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
172
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16805911-Adolescent,
pubmed-meshheading:16805911-Aminoglycosides,
pubmed-meshheading:16805911-Antibodies, Monoclonal,
pubmed-meshheading:16805911-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16805911-Antigens, CD,
pubmed-meshheading:16805911-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:16805911-Antineoplastic Agents,
pubmed-meshheading:16805911-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16805911-Child,
pubmed-meshheading:16805911-Child, Preschool,
pubmed-meshheading:16805911-Female,
pubmed-meshheading:16805911-Humans,
pubmed-meshheading:16805911-Immunotoxins,
pubmed-meshheading:16805911-Infant,
pubmed-meshheading:16805911-Leukemia, Myeloid,
pubmed-meshheading:16805911-Male,
pubmed-meshheading:16805911-Recurrence,
pubmed-meshheading:16805911-Remission Induction,
pubmed-meshheading:16805911-Retrospective Studies
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
|
|
pubmed:affiliation |
Unité de Pédiatrie à Orientation Hématologique, Hôpital Saint-Louis, Paris, France. benoit.brethon@sls.aphp.fr
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
